

Adipose-specific *CLSTN3B* gene associates with human obesity

Under genetic and environmental cues, adipose tissue retains a dynamically active organ that plays a critical role in the regulation of energy homeostasis [1]. The abnormal expansion of adipose tissue has been implicated in the pathogenesis of several metabolic disorders, including obesity, type 2 diabetes, and cardiovascular disease [2]. Despite significant efforts, the specific genes associated with adipose function and their impact on whole-body metabolic remain largely elusive.

Calsynenin 3 β (CLSTN3 β), a novel adipocyte-specific product of *Clstn3* gene locus. Plays a critical role in promoting brown adipose thermogenesis in mice via enhancing sympathetic innervation [3]. Later research showed that CLSTN3 β regulates the formation and function of lipid droplets, facilitating fatty acid oxidation in mouse thermogenic adipocytes [4]. However, the presence of *CLSTN3B* gene in human adipose tissue remains unclear. Bai et al. previously reported a discordant expression pattern on *Clstn3/CLSTN3* locus between mice and humans [5]. In their recent publication in *Life Metabolism* titled “Transcript profile of *CLSTN3B* gene in human white adipose tissue is associated with obesity and mitochondrial gene program”, the authors revealed an association between the *CLSTN3B* transcript profile in human white adipose tissue and individual metabolic status and mitochondrial gene program [6].

The diversity of human white adipose tissue composition depends on the anatomical location [7]. Subcutaneous adipose tissue (SAT) comprises the majority of human body fat, while the smaller amount of visceral adipose tissue (VAT) is considered more pernicious and associated with metabolic disorders [8]. Despite the relatively low abundance of mitochondria in white adipocytes, emerging evidence suggests their crucial role in maintaining white adipocyte function [9]. Comparative studies have demonstrated higher expression of thermogenic genes in human visceral adipocytes compared to subcutaneous adipocytes [10]. Hence, a comprehensive understanding of the mitochondrial regulation in human adipose tissue is imperative to develop targeted and effective strategies for understanding adipose biology and promoting overall health.

In this novel study, the authors conducted an investigation on the association between the transcript profile of *CLSTN3B* and metabolic status in adipose tissue. They observed a significant reduction in the relative abundance of *CLSTN3B* transcript in abdominal SAT and VAT samples from a total of 210 participants with BMI increased. Moreover, they found that the transcript levels of *CLSTN3B* were significantly correlated with various metabolic parameters, including adipose mass and function measures, as well as whole-body insulin resistance. To further explore the potential role of *CLSTN3B* in human adipose tissue, co-expression analysis was performed on VAT, which revealed that the

positively correlated genes were enriched in mitochondrial gene programs, indicating that *CLSTN3B* may participate in maintaining mitochondrial activities. Lastly, the authors demonstrated that the protein-coding variant rs7296261 of *CLSTN3B* gene was linked with a high BMI and exacerbated insulin resistance among participants, providing further insight into the underlying mechanisms of the association between *CLSTN3B* and metabolic disorders.

Taken together, the findings from this study reveal a negative association between the transcript profile of *CLSTN3B* gene in human adipose tissue and obesity. Moreover, the study highlights the potential role of *CLSTN3B* in modulating mitochondrial homeostasis. These findings suggest that targeted upregulation of the *CLSTN3B* gene in adipose tissue may hold therapeutic potentials for the treatment of obesity and related metabolic disorders.

Financial support

None.

CRediT authorship contribution statement

Wenfei Li: Writing – original draft, Writing – review & editing. **Quanxin Jiang:** Writing – original draft, Writing – review & editing. **Suzhen Chen:** Conceptualization, Investigation, Supervision, Writing – original draft, Writing – review & editing. **Junli Liu:** Conceptualization, Investigation, Supervision, Validation, Writing – original draft, Writing – review & editing.

Declaration of competing interest

No conflict of interest to disclose.

References

- [1] Sakers A, De Siqueira MK, Seale P, Villanueva CJ. Adipose-tissue plasticity in health and disease. *Cell* 2022;185:419–46.
- [2] Chouchani ET, Kajimura S. Metabolic adaptation and maladaptation in adipose tissue. *Nat Metab* 2019;1:189–200.
- [3] Zeng X, Ye M, Resch JM, et al. Innervation of thermogenic adipose tissue via a calsynenin 3 β -S100b axis. *Nature* 2019;569:229–35.
- [4] Qian K, Tol MJ, Wu J, et al. CLSTN3 β enforces adipocyte multilocularity to facilitate lipid utilization. *Nature* 2023;613:160–8.
- [5] Bai N, Lu X, Jin L, et al. CLSTN3 gene variant associates with obesity risk and contributes to dysfunction in white adipose tissue. *Mol Metabol* 2022;63:101531.
- [6] Bai N, Lu X, Wang Y, et al. Transcript profile of *CLSTN3B* gene in human white adipose tissue is associated with obesity and mitochondrial gene program. *Life Metab* 2023;2:load037.
- [7] Zwick RK, Guerrero-Juarez CF, Horsley V, Plikus MV. Anatomical, physiological, and functional diversity of adipose tissue. *Cell Metabol* 2018;27:68–83.

<https://doi.org/10.1016/j.metop.2024.100269>

Received 1 January 2024; Accepted 1 January 2024

Available online 2 January 2024

2589-9368/© 2024 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

- [8] Hagberg CE, Spalding KL. White adipocyte dysfunction and obesity-associated pathologies in humans. *Nat Rev Mol Cell Biol* 2023.
- [9] Zhu Q, An YA, Scherer PE. Mitochondrial regulation and white adipose tissue homeostasis. *Trends Cell Biol* 2022;32:351–64.
- [10] Hruska P, Kucera J, Pekar M, et al. Proteomic signatures of human visceral and subcutaneous adipocytes. *J Clin Endocrinol Metab* 2022;107:755–75.

Wenfei Li, Quanxin Jiang, Suzhen Chen **, Junli Liu *
Department of Endocrinology and Metabolism, Shanghai Diabetes Institute, Shanghai Clinical Center for Diabetes, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Key Clinical Center for Metabolic Disease, Shanghai Jiao

Tong University School of Medicine Affiliated Sixth People's Hospital, Shanghai, 200233, China

* Corresponding author.

** Corresponding author.

E-mail addresses: cszdream@163.com (S. Chen), liujunli@sjtu.edu.cn (J. Liu).